What if the $35 insulin cap is extended to all payers?
An all-payer $35 insulin cap is largely priced — Lilly/Novo/Sanofi already cut US insulin list prices in 2023 and insulin is a small share of their GLP-1-dominated P&Ls; biosimilar share-shift is the second-order trade. The move is marginal for the makers and immaterial for the index. The small risk-off crypto cascade overstates an already-discounted, narrow event.
how we built this number — every step
The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.
What it would mean
If this plays out, it is a mixed shock. Federal $35 insulin cap extended to all payers compresses insulin-maker margins and accelerates biosimilar share shifts. The trigger decomposes into signed root‑shocks — Risk appetite ▼ — which propagate through our causal graph to the markets below.
If it happens — the markets it would move
Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.
| Market | Class | Projected move | |
|---|---|---|---|
| 1 | Solana SOLon Hyperliquid 📈 chart | Crypto | ▼ -0.3% hist -11.38–+1.49% · other way -1.0% (n=12) |
| 2 | Hyperliquid (HYPE) HYPEon Hyperliquid | Crypto | ▼ -0.3% model prior · unmeasured |
| 3 | MicroStrategy MSTRon Hyperliquid 📈 chart | Equity | ▼ -0.3% hist -1.37–+0.41% · other way +24.57% (n=12) |
| 4 | Ether ETHon Hyperliquid 📈 chart | Crypto | ▼ -0.2% hist -7.76–+2.36% · other way +4.71% (n=12) |
| 5 | Nasdaq 100 NDXon Hyperliquid 📈 chart | Index | ▼ -0.2% hist -0.39–+0.03% · other way -0.29% (n=12) |
| 6 | Bitcoin BTCon Hyperliquid 📈 chart | Crypto | ▼ -0.2% hist -4.97–+1.69% · other way +5.56% (n=12) |
| 7 | Tech sector XLK 📈 chart | Equity | ▼ -0.1% hist -0.17–+0.13% · other way -0.38% (n=12) |
Probable recommendation
Why we may diverge from history
Trust the cascade-short on MSTR; insulin caps cannot move a bitcoin-treasury stock, and the +14.8% history is entirely 2024-25 BTC bull beta, regime-biased not causal.
Historical precedent — what analogous events actually did
Across 40 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.
| Asset | History says | Abnormal (20d · 5d) | Hit | n | Confidence | vs cascade |
|---|---|---|---|---|---|---|
| SOL SOL | SHORT | -9.2% · 5d -7.6% | 75% | 40 | 0.38 | ✓ matches cascade |
| ETH ETH | SHORT | -6.9% · 5d -5.3% | 62% | 40 | 0.19 | ✓ matches cascade |
| NDX NDX | SHORT | -0.2% · 5d -0.9% | 62% | 40 | 0.18 | ✓ matches cascade |
| Bitcoin BTC | SHORT | -4.5% · 5d -3.4% | 60% | 40 | 0.15 | ✓ matches cascade |
| Gold XAU | LONG | +0.2% · 5d -0.3% ↺ fades | 57% | 40 | 0.13 | · |
| MSTR MSTR | SHORT | -1.1% · 5d -3.2% | 55% | 40 | 0.10 | ✓ matches cascade |
| High-yield credit HYG | SHORT | -0.0% · 5d +0.2% ↺ fades | 55% | 40 | 0.07 | · |
| US dollar DXY | SHORT | -0.0% · 5d -0.1% | 53% | 40 | 0.05 | · |
| Volatility VIX | SHORT | -0.8% · 5d +0.1% ↺ fades | 53% | 40 | 0.04 | · |
| 10y yield DGS10 | LONG | +2bp · 5d +1bp | 53% | 40 | 0.04 | · |
| XLK XLK | LONG | +0.2% · 5d -0.4% ↺ fades | 50% | 40 | 0.00 | ⚠ differs |
Why this probability
All-payer $35 insulin cap needs legislation; popular but stalled; biosimilar shift already underway. A base‑rate‑anchored prior, continuously scored against what actually happens — not a forecast.